title: Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine.
abstract: The Ts65Dn mouse is the best-studied animal model for Down syndrome. In the experiments described here, NMDA-mediated or mGluR-mediated LTD was induced in the CA1 region of hippocampal slices from Ts65Dn and euploid control mice by bath application of 20 µM NMDA for 3 min and 50 µM DHPG for 5 min, respectively. We found that Ts65Dn mice display exaggerated NMDA-induced, but not mGluR-induced, LTD in the CA1 region of the hippocampus compared with euploid control animals. In addition, this abnormal level of LTD can be pharmacologically rescued by the NMDA receptor antagonist memantine.
authors.affiliation: Neuroscience Training Program, University of Colorado, Anschutz Medical Campus, Aurora, Colorado 80045, USA.
authors.forename: Jonah J
authors.initials: JJ
authors.lastname: Scott-McKean
authors.forename: Alberto C S
authors.initials: AC
authors.lastname: Costa
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D004195:Disease Models, Animal; D004314:Down Syndrome / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D004558:Electric Stimulation; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology*; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects / Q000235:genetics; D006624:Hippocampus / Q000187:drug effects / Q000473:pathology*; D066298:In Vitro Techniques; D036881:Long-Term Synaptic Depression / Q000187:drug effects* / Q000235:genetics; D008559:Memantine / Q000627:therapeutic use*; D008734:Methoxyhydroxyphenylglycol / Q000031:analogs & derivatives / Q000494:pharmacology; D051379:Mice; D008817:Mice, Mutant Strains; D016202:N-Methylaspartate / Q000494:pharmacology*; D013997:Time Factors; D014314:Trisomy / Q000473:pathology
chemical_list: D018690:Excitatory Amino Acid Agonists; D018691:Excitatory Amino Acid Antagonists; D008734:Methoxyhydroxyphenylglycol; D016202:N-Methylaspartate; C010117:3,4-dihydroxyphenylglycol; D008559:Memantine
references.citation: J Med Genet. 2008 Aug;45(8):498-9
references.pmid: 18413371
references.citation: J Alzheimers Dis. 2010;21(1):277-90
references.pmid: 20421694
references.citation: Neuropharmacology. 1999 Dec;38(12):1917-20
references.pmid: 10608287
references.citation: J Physiol. 1997 Feb 15;499 ( Pt 1):27-46
references.pmid: 9061638
references.citation: Clin Pharmacol Ther. 2006 Jan;79(1):134-43
references.pmid: 16413248
references.citation: Nature. 1994 May 19;369(6477):235-9
references.pmid: 7514273
references.citation: BMC Neurosci. 2005 Jul 22;6:48
references.pmid: 16042781
references.citation: Nat Neurosci. 2007 Apr;10(4):411-3
references.pmid: 17322876
references.citation: Nat Rev Genet. 2005 Feb;6(2):137-47
references.pmid: 15640809
references.citation: Cell. 1991 Dec 20;67(6):1047-58
references.pmid: 1760838
references.citation: Birth Defects Res A Clin Mol Teratol. 2006 Nov;76(11):747-56
references.pmid: 17051527
references.citation: Anesthesiology. 2000 Jan;92(1):228-36
references.pmid: 10638920
references.citation: Neurosci Lett. 2005 Jul 15;382(3):317-22
references.pmid: 15925111
references.citation: Nat Genet. 1995 Oct;11(2):177-84
references.pmid: 7550346
references.citation: Proc Natl Acad Sci U S A. 2002 May 28;99(11):7746-50
references.pmid: 12032354
references.citation: Neuron. 2004 Sep 30;44(1):5-21
references.pmid: 15450156
references.citation: Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8987-92
references.pmid: 12851457
references.citation: Am J Obstet Gynecol. 2008 Mar;198(3):313.e1-4
references.pmid: 18313453
references.citation: Behav Brain Res. 2010 Jan 5;206(1):52-62
references.pmid: 19720087
references.citation: Genes Brain Behav. 2008 Oct;7(7):810-20
references.pmid: 19125866
references.citation: Neuron. 1995 Aug;15(2):417-26
references.pmid: 7544143
references.citation: Neurobiol Dis. 2008 Dec;32(3):377-84
references.pmid: 18773961
references.citation: Nat Neurosci. 2005 Aug;8(8):1043-50
references.pmid: 16025109
references.citation: J Neurosci. 2004 Sep 15;24(37):8153-60
references.pmid: 15371516
references.citation: Neurosci Biobehav Rev. 1997 Jul;21(4):455-68
references.pmid: 9195603
references.citation: Annu Rev Neurosci. 2002;25:103-26
references.pmid: 12052905
references.citation: Dev Neurosci. 2011;33(5):404-13
references.pmid: 21865664
references.citation: Trends Neurosci. 2004 Jul;27(7):370-7
references.pmid: 15219735
references.citation: Behav Brain Res. 2011 Aug 10;221(2):610-22
references.pmid: 20363261
references.citation: Sci Transl Med. 2011 Jan 5;3(64):64ra1
references.pmid: 21209411
references.citation: Cell. 2001 Nov 16;107(4):477-87
references.pmid: 11719188
references.citation: J Neurochem. 2009 Jul;110(1):157-69
references.pmid: 19453946
references.citation: Physiol Behav. 1999 Dec 1-15;68(1-2):211-20
references.pmid: 10627083
references.citation: Neurosci Lett. 1995 Aug 4;195(2):137-9
references.pmid: 7478269
references.citation: Mamm Genome. 2011 Jun;22(5-6):261-71
references.pmid: 21400203
references.citation: Dev Neurosci. 2011;33(5):414-27
references.pmid: 21893967
references.citation: Neuropsychopharmacology. 2008 Jun;33(7):1624-32
references.pmid: 17700645
references.citation: Trends Pharmacol Sci. 2010 Feb;31(2):66-73
references.pmid: 19963286